1.Current aspects in red blood cell substitutes.
Yanfeng WANG ; Jilun PAN ; Yaoting YU
Journal of Biomedical Engineering 2004;21(3):490-494
Red blood cell substitutes are a group of oxygen carriers designed to temporarily replace transfused blood. Current developing products include perfluorocarbon-based and hemoglobin-based oxygen carrier. Each product is unique in its limitations and advantages. A number of products are in advanced clinical trials and nearing market. When they are available for use it is likely that development will accelerate and even better products will substantially alleviate the world-wide shortage of blood for transfusion.
Blood Substitutes
;
chemistry
;
pharmacology
;
therapeutic use
;
Fluorocarbons
;
chemistry
;
pharmacology
;
therapeutic use
;
Hemoglobins
;
chemistry
;
pharmacology
;
therapeutic use
;
Humans
;
Oxygen
;
metabolism
;
Recombinant Proteins
;
chemistry
;
pharmacology
;
therapeutic use
2.A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
Xiu-Zhen ZHANG ; Bo WANG ; Jun YANG ; Miao XUAN ; Li-Ge SONG ; Hong LI ; Xiao-Hui GUO ; Xiao-Feng LÜ ; Qing-Yun XUE ; Gang-Yi YANG ; Qiu-He JI ; Jie SHEN ; Zhi-Min LIU ; Cheng-Jiang LI ; Tian-Feng WU ; Xiao-Cui TONG ; Yuan JIA
Chinese Medical Journal 2009;122(24):2933-2938
BACKGROUNDRecombinant human parathyroid hormone (1-34) (rhPTH (1-34)) given by injection is a new seventh class drug of biological products, which is prepared by adopting gene recombination technique. rhPTH (1-34) is mainly used to treat osteoporosis, especially for postmenopausal women. This study compared the clinical efficacy and safety of rhPTH (1-34) with elcatonin for treating postmenopausal women with osteoporosis in 11 urban areas of China.
METHODSTwo hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study. They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly. Lumbar spine (L1-4) and femoral neck bone mineral density (BMD), as well as biochemical markers of bone turnover were measured. Adverse events were recorded.
RESULTSrhPTH (1-34) increased lumbar BMD significantly more than did elcatonin at 3 months and 6 months (2.38% vs 0.59%, P < 0.05; 5.51% vs 1.55%, P < 0.01), but there were no significant increases of BMD in these two groups at femoral neck. There were larger mean increases in bone markers in the rhPTH (1-34) group than in the elcatonin group at 3 months and 6 months (serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; urinary N-telopeptide/creatinine (NTX/Cr) 48.91% vs -5.32%; 68.82% vs -10.86%). Both treatments were well tolerated and there were no significant differences detected between the two groups in the proportion of any adverse events and any serious adverse events (67.0% vs 59.0%; 0 vs 0).
CONCLUSIONSrhPTH (1-34) has more positive effects on bone formation, as shown by the larger increments of lumbar BMD and bone formation markers, than elcatonin, with only mild adverse events and no significant change in the liver, kidney or hematological indices.
Aged ; Calcitonin ; analogs & derivatives ; pharmacology ; therapeutic use ; Female ; Humans ; Middle Aged ; Osteogenesis ; drug effects ; Osteoporosis, Postmenopausal ; drug therapy ; Parathyroid Hormone ; pharmacology ; therapeutic use ; Recombinant Proteins ; pharmacology ; therapeutic use
3.Effect of cyclosporine and simulect mono and combination therapy on cardiac allo-transplantation in rats.
Hai-Bo XIONG ; Sui-Sheng XIA ; Zu-Fal HUANG ; Qi-Fa YE ; Hao WEN
Journal of Central South University(Medical Sciences) 2005;30(5):549-552
OBJECTIVE:
To observe the effect of cyclosporine and simulect mono or combination therapy on cardiac allo-transplantation in rats.
METHODS:
Recipients with allografts were treated with different doses of cyclosporine and/or simulect after cardiac allo-transplantation. Graft survival time was observed; the histopathological examination of graft tissues was performed; and levels of serum IL-2 and IL-4 were determined.
RESULTS:
Mono or combination therapy with cyclosporine and/or simulect increased the survival of cardiac allografts. With the prolongation of survival time of the grafts, the rejection of grafts was moderated. The serum IL-2 level increased in acute rejected grafts; the serum IL-4 level increased evidently in long survival grafts.
CONCLUSION
Cyclosporine and simulect have an effect in the prolongation of cardiac allograft survival in rats, and the combination therapy shows an evident synergistic effect.
Animals
;
Antibodies, Monoclonal
;
pharmacology
;
therapeutic use
;
Basiliximab
;
Combined Modality Therapy
;
Cyclosporine
;
pharmacology
;
therapeutic use
;
Female
;
Graft Rejection
;
immunology
;
Heart Transplantation
;
adverse effects
;
Immunosuppressive Agents
;
pharmacology
;
therapeutic use
;
Rats
;
Rats, Sprague-Dawley
;
Rats, Wistar
;
Recombinant Fusion Proteins
;
pharmacology
;
therapeutic use
4.Recombinant human gapM1 expressed in Pichia pastoris and its anti-diabetic effect.
Xiang MEI ; Renqian DU ; Xi LI ; Haiyan HUANG ; Min YU ; Qiqun TANG
Chinese Journal of Biotechnology 2009;25(8):1211-1217
Adiponectin is an adipokine predominantly synthesized and secreted by adipocytes in the white adipose tissue, and it can lower the blood glucose level and increase free fatty acid oxidation. In the current study, we developed the globular domain of adiponectin (gapM1) to treat type II diabetes. In both flask and fermentor, we cultivated Pichia pastoris expressing recombinant gapM1 and established the purification procedure by using gel filtration and anion exchange chromatography. To evaluate the biological activity of recombinant gapM1, we used rat type II diabetes model fed high-fat diet in combination with low-dose STZ (Streptozocin) induction. We purified 200 mg gapM1 with purity of 96% from 10 liters of supernatant. The recombinant gapM1 significantly lowered blood glucose (34.2%), serum triglyceride (79.6%) and total cholesterol (62.1%) in type II diabetes induced rat. Therefore, the recombinant human gapM1 is successfully expressed in Pichia pastoris and effectively treated type II diabetes in rat models.
Adiponectin
;
biosynthesis
;
genetics
;
pharmacology
;
therapeutic use
;
Animals
;
Diabetes Mellitus, Experimental
;
drug therapy
;
Genetic Vectors
;
Hypoglycemic Agents
;
pharmacology
;
therapeutic use
;
Male
;
Pichia
;
genetics
;
metabolism
;
Random Allocation
;
Rats
;
Rats, Sprague-Dawley
;
Recombinant Proteins
;
biosynthesis
;
genetics
;
pharmacology
;
therapeutic use
5.Constitutive expression of human angiostatin in Pichia pastoris using glycerol as only carbon source.
Fa-Zhi TU ; Ce-Yi FU ; Tian-Yuan ZHANG ; Jin-Xian LUO ; Ai-Lian ZHANG
Chinese Journal of Biotechnology 2007;23(5):902-906
Carbon source plays an important role in the constitutive expression of foreign proteins in Pichia pastoris. In present study, glucose , glycerol , methanol and oil acid, was used respectively as the only carbon source to constitutively express hAS in Pichia pastoris GS115 (pGAP9K-AS)in shaking flask. The result shows that oleic acid is the best (163 mg/L) compared with glycerol (83mg/L), glucose (76 mg/L)and methanol (57 mg/L). Since oleic acid is insoluble in water, glycerol was used as the carbon source in the high-density cell culture of GS115 (pGAP9K-AS) in a 30 liter bioreactor and 169 mg/L of angiostatin was obtained after 48h of culture. The expressed angiostatin is immunologically active as shown by Western blotting. The recombinant hAS inhibits bFGF induced CAM angiogenesis and suppresses the growth of B16 melanoma in C57BL/6J mice. The tumor inhibition rate is 90% after 12 days of treatment. Statistics analysis revealed that the tumor volume difference of mice between the hAS group and PBS group is prominent (P < 0.01).
Angiogenesis Inhibitors
;
biosynthesis
;
genetics
;
therapeutic use
;
Angiostatins
;
biosynthesis
;
genetics
;
therapeutic use
;
Animals
;
Bioreactors
;
microbiology
;
Culture Media
;
pharmacology
;
Fermentation
;
Glycerol
;
pharmacology
;
Humans
;
Melanoma, Experimental
;
drug therapy
;
Mice
;
Mice, Inbred C57BL
;
Pichia
;
genetics
;
growth & development
;
metabolism
;
Recombinant Proteins
;
biosynthesis
;
genetics
;
therapeutic use
6.A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
Byung Chul YOU ; Young Seok KIM ; Hun Il KIM ; Se Hun KIM ; Seung Sik PARK ; Yu Ri SEO ; Sang Gyune KIM ; Se Whan LEE ; Hong Soo KIM ; Soung Won JEONG ; Jae Young JANG ; Boo Sung KIM
Clinical and Molecular Hepatology 2012;18(3):272-278
BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN alpha-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than for patients in Western countries, current guidelines might result in Korean patients being overdosed with RBV. METHODS: We retrospectively reviewed the medical records of patients with genotype 1 CHC who were treated with Peg-IFN alpha-2b and RBV combination therapy. We divided the patients into groups A (> or =15 mg/kg/day, n=23) and B (<15 mg/kg/day, n=26), given that the standard dose is 15 mg/kg/day. The clinical course in terms of the virologic response, adverse events, and dose modification rate was compared between the two groups after therapy completion. RESULTS: The early response rates (92.0% vs. 83.3%, P=0.634) and sustained virologic response rates (82.6% vs. 73.1%, P=0.506) did not differ significantly between the two groups. During the treatment period, the RBV dose reduction rate was significantly higher in group A than in group B (60.9% vs. 23.1%, P=0.01). CONCLUSIONS: RBV dose reduction is performed frequently when patients are treated according to the current Korean guidelines. Given that lowering the RBV dose did not appear to decrease the virologic response during therapy, reducing RBV doses below the current Korean guideline may be effective for treatment, especially in low-weight patients.
Antiviral Agents/pharmacology/*therapeutic use
;
Body Mass Index
;
Body Weight
;
Dose-Response Relationship, Drug
;
Drug Administration Schedule
;
Drug Therapy, Combination
;
Female
;
Genotype
;
Hepacivirus/drug effects
;
Hepatitis C, Chronic/*drug therapy/virology
;
Humans
;
Interferon-alpha/pharmacology/*therapeutic use
;
Male
;
Polyethylene Glycols/pharmacology/*therapeutic use
;
RNA, Viral/analysis
;
Recombinant Proteins/pharmacology/therapeutic use
;
Retrospective Studies
;
Ribavirin/pharmacology/*therapeutic use
;
Sex Factors
;
Treatment Outcome
7.Effect of recombinant human erythropoietin on bcl-2 protein expression in the retina in a rabbit model of acute high intraocular pressure.
Jian-ming WANG ; Yan-ping SONG ; Nai-xue SUN ; Na HUI ; Shi-ping ZHAO ; Kai HU
Journal of Southern Medical University 2010;30(3):552-554
OBJECTIVETo investigate the effect of recombinant human erythropoietin (rhEPO) on the expression of bcl-2 protein in the retina of rabbits with acute high intraocular pressure and explore the mechanism underlying the protective effect of rhEPO on the retina against ischemia-reperfusion injury.
METHODSrhEPO was injected subcutaneously in the ear of a rabbit model of acute high intraocular pressure induced by physiological saline perfusion into the anterior chamber. Bcl-2 protein expression in the retina of the rabbits was observed by immunohistochemical staining on days 1, 3, 7, and 14 after retinal ischemia-reperfusion and compared with that in normal rabbits and untreated rabbit models.
RESULTSbcl-2-positive cells were observed in the retina of normal rabbits with a mean positive cell number of 10.5-/+1.2 in each high-power visual field. Compared with that in the normal control group, the number of the positive cells decreased significantly in both the model group and EPO group (P<0.05, P<0.01), but the latter group showed a significantly greater number than the former (P<0.05 at day 7 and P<0.01 at day 14).
CONCLUSIONSystemic administration of rhEPO can up-regulate the expression of bcl-2 protein in the retina of rabbits with acute high intraocular pressure, which is probably one of the mechanisms for the protective effect of rhEPO on the retina against ischemia-reperfusion injury.
Animals ; Erythropoietin ; pharmacology ; therapeutic use ; Female ; Humans ; Male ; Ocular Hypertension ; drug therapy ; metabolism ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; Rabbits ; Random Allocation ; Recombinant Proteins ; Retina ; metabolism
8.The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.
Hee Jae JUNG ; Young Seok KIM ; Sang Gyune KIM ; Yun Nah LEE ; Soung Won JEONG ; Jae Young JANG ; Sae Hwan LEE ; Hong Soo KIM ; Boo Sung KIM
Clinical and Molecular Hepatology 2014;20(1):38-46
BACKGROUND/AIMS: Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the association between CHC treatment response and lipid profile and IR change during treatment. METHODS: In total, 203 CHC patients were reviewed retrospectively between January 2005 and December 2011 at Soon Chun Hyang University Hospital. The lipid profile, homeostasis model for assessment (HOMA) of IR (HOMA-IR), and HOMA of beta cells (HOMA-beta) were evaluated before interferon plus ribavirin therapy (BTx), at the end of treatment (DTx), and 24 weeks after the end of treatment (ATx). RESULTS: A sustained virologic response (SVR) was achieved by 81% of all patients (49/60), 60% (n=36) of whom possessed genotype 1, with the remainder being non-genotype-1 (40%, n=24). Apart from age, which was significantly higher in the non-SVR group (SVR, 48.0+/-11.2 years, mean+/-SD; non-SVR, 56.6+/-9.9 years; P<0.01), there were no significant differences in the baseline characteristics between the SVR and non-SVR groups. In the SVR group, low density lipoprotein-cholesterol (LDL-C) had significantly changed at DTx and ATx compared to BTx. In addition, HOMA-IR and HOMA-beta were significantly changed at DTx in the SVR group. Among those with a high baseline insulin resistance (HOMA-IR >2.5), HOMA-IR was significantly changed at DTx in the SVR group. CONCLUSIONS: LDL-C appears to be associated with HCV treatment in SVR patients. Furthermore, eradication of HCV may improve whole-body IR and insulin hypersecretion, as well as high baseline insulin resistance (HOMA-IR >2.5).
Adult
;
Aged
;
Antiviral Agents/pharmacology/*therapeutic use
;
Cholesterol/blood
;
Drug Therapy, Combination
;
Female
;
Genotype
;
Hepacivirus/genetics
;
Hepatitis C, Chronic/*drug therapy
;
Humans
;
*Insulin Resistance
;
Interferon-alpha/pharmacology/*therapeutic use
;
Lipid Metabolism/drug effects
;
Male
;
Middle Aged
;
Polyethylene Glycols/pharmacology/*therapeutic use
;
Recombinant Proteins/pharmacology/therapeutic use
;
Ribavirin/*therapeutic use
;
Treatment Outcome
;
Triglycerides/blood
9.Intrathecal Gabapentin Increases Interleukin-10 Expression and Inhibits Pro-Inflammatory Cytokine in a Rat Model of Neuropathic Pain.
Byung Sang LEE ; In Gu JUN ; Sung Hoon KIM ; Jong Yeon PARK
Journal of Korean Medical Science 2013;28(2):308-314
We examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathic pain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (IL-10) expression in a rat model of neuropathic pain. The anti-allodynic effect of intrathecal gabapentin was examined over a 7-day period. The anti-allodynic effects of IL-10 was measured, and the effects of anti-IL-10 antibody on the gabapentin were assessed. On day 7, the concentrations of pro-inflammatory cytokines and IL-10 were measured. Gabapentin produced an anti-allodynic effect over the 7-day period, reducing the expression of pro-inflammatory cytokines but increasing the expression of IL-10 (TNF-alpha, 316.0 +/- 69.7 pg/mL vs 88.8 +/- 24.4 pg/mL; IL-1beta, 1,212.9 +/- 104.5 vs 577.4 +/- 97.1 pg/mL; IL-6, 254.0 +/- 64.8 pg/mL vs 125.5 +/- 44.1 pg/mL; IL-10, 532.1 +/- 78.7 pg/mL vs 918.9 +/- 63.1 pg/mL). The suppressive effect of gabapentin on pro-inflammatory cytokine expression was partially blocked by the anti-IL-10 antibody. Expression of pro-inflammatory cytokines was significantly attenuated by daily injections of IL-10. The anti-allodynic effects of gabapentin may be caused by upregulation of IL-10 expression in the spinal cord, which leads to inhibition of the expression of pro-inflammatory cytokines in the spinal cords.
Amines/pharmacology/*therapeutic use
;
Analgesics/pharmacology/*therapeutic use
;
Animals
;
Antibodies/immunology/pharmacology
;
Behavior, Animal/drug effects
;
Cyclohexanecarboxylic Acids/pharmacology/*therapeutic use
;
Cytokines/*metabolism
;
Disease Models, Animal
;
Injections, Spinal
;
Interleukin-10/genetics/immunology/*metabolism
;
Male
;
Neuralgia/*drug therapy/metabolism/pathology
;
Rats
;
Rats, Sprague-Dawley
;
Recombinant Proteins/biosynthesis/genetics/pharmacology
;
Spinal Cord/metabolism
;
Up-Regulation
;
gamma-Aminobutyric Acid/pharmacology/*therapeutic use
10.Experimental study of artificial bone composite of bicoral, rhBMP-2 and PLA in repairing calvarial defects.
Xinmei CHEN ; Tianqiu MAO ; Yimin DAI
West China Journal of Stomatology 2003;21(6):474-476
OBJECTIVETo study the effects of artificial bone composite of bicoral, rhBMP-2 and PLA in repairing calvarial critical-size defects.
METHODSCalvarial defects in 24 rabbits were surgically made and then half of the defects were repaired with the artificial composite bone. Another half of them were repaired with bicoral/PLA composite and served as controls. Four rabbits in each group were sacrificed at 4, 8, 12 weeks after operation, respectively. The treatment effects were evaluated with scanning electron microscopy and mechanical strength testing.
RESULTSNew bone was observed not only in the periphery, but also inside the artificial bone in both groups, but earlier and more new bone formation was observed in treatment group compared with control group. The mechanical strength test showed that the artificial bone in two groups, which had same mechanical strength before implantation, had significant different mechanical strength after operation. The strength of the artificial composite bone was higher than that of controls and was same with normal rabbit calvarial bone.
CONCLUSIONThe artificial composite bone possess a highly repairing ability, and the healing in bone defects may be accomplished by both osteoinductive and osteoconductive mechanism. The material may be used as a good substitute for bone grafting.
Animals ; Anthozoa ; Biocompatible Materials ; Bone Morphogenetic Protein 2 ; Bone Morphogenetic Proteins ; pharmacology ; therapeutic use ; Bone Regeneration ; drug effects ; Bone Substitutes ; therapeutic use ; Implants, Experimental ; Lactic Acid ; therapeutic use ; Polyesters ; Polymers ; therapeutic use ; Rabbits ; Recombinant Proteins ; pharmacology ; therapeutic use ; Skull ; injuries ; surgery ; Transforming Growth Factor beta